Lansforsakringar Fondforvaltning AB publ Purchases Shares of 8,907 Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Lansforsakringar Fondforvaltning AB publ bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 8,907 shares of the biopharmaceutical company's stock, valued at approximately $426,000.

Other large investors also recently bought and sold shares of the company. Venturi Wealth Management LLC acquired a new position in Halozyme Therapeutics in the fourth quarter valued at about $69,000. Shaker Investments LLC OH increased its stake in Halozyme Therapeutics by 12.3% during the fourth quarter. Shaker Investments LLC OH now owns 75,326 shares of the biopharmaceutical company's stock worth $3,601,000 after purchasing an additional 8,249 shares during the period. Jennison Associates LLC purchased a new stake in Halozyme Therapeutics during the fourth quarter worth about $731,000. Foster & Motley Inc. increased its stake in Halozyme Therapeutics by 118.6% during the fourth quarter. Foster & Motley Inc. now owns 23,280 shares of the biopharmaceutical company's stock worth $1,113,000 after purchasing an additional 12,630 shares during the period. Finally, Koa Wealth Management LLC increased its stake in Halozyme Therapeutics by 10.6% during the fourth quarter. Koa Wealth Management LLC now owns 82,407 shares of the biopharmaceutical company's stock worth $3,940,000 after purchasing an additional 7,924 shares during the period. Institutional investors and hedge funds own 97.79% of the company's stock.

Analysts Set New Price Targets

HALO has been the topic of a number of recent research reports. HC Wainwright reiterated a "buy" rating and set a $72.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, May 29th. Leerink Partners lowered shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target on the stock. in a research note on Tuesday, May 13th. Morgan Stanley lowered shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and cut their price target for the stock from $73.00 to $62.00 in a research note on Wednesday, May 14th. Leerink Partnrs lowered shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, May 13th. Finally, Benchmark lowered shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $61.90.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 503 shares of the stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total value of $32,217.15. Following the transaction, the director now directly owns 33,108 shares in the company, valued at $2,120,567.40. This represents a 1.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.40% of the stock is currently owned by insiders.

Halozyme Therapeutics Stock Down 4.2%

Shares of HALO stock traded down $2.33 during trading hours on Tuesday, reaching $53.31. 3,099,309 shares of the stock were exchanged, compared to its average volume of 1,644,997. The business's fifty day moving average is $58.52 and its two-hundred day moving average is $55.71. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a 12-month low of $42.01 and a 12-month high of $70.51. The firm has a market capitalization of $6.57 billion, a P/E ratio of 15.54, a P/E/G ratio of 0.42 and a beta of 1.26.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The firm had revenue of $264.86 million for the quarter, compared to analyst estimates of $231.21 million. During the same period in the prior year, the firm earned $0.79 earnings per share. The business's quarterly revenue was up 35.2% compared to the same quarter last year. As a group, research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.